Literature DB >> 21453441

Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort.

S Perez-Lloret1, L Nègre-Pagès, A Ojero-Senard, P Damier, A Destée, F Tison, M Merello, O Rascol.   

Abstract

INTRODUCTION: Abnormal oro-buccal functions including dysarthria, sialorrhea and dysphagia commonly affect patients with Parkinson's disease (PD).
OBJECTIVES: To estimate the prevalence of such oro-buccal symptoms at baseline in the first 419 patients with PD included in the COPARK cohort and to analyze their correlations with patients' demographics, clinical characteristics, and drugs consumption.
METHODS: Patients were assessed using the Unified PD Rating Scale, the Hospital Anxiety and Depression Scale, and the PDQ-39. Dysarthria, sialorrhea, and dysphagia were defined as UPDRS items 5, 6, or 7 ≥ 1.
RESULTS: Dysarthria, sialorrhea, or dysphagia were present in 51%, 37%, or 18% out of the 419 patients, respectively. At least one of these symptom was present in 267/419 patients (65%), whilst a combination of symptoms was present in 136/419 (33%). Logistic regression showed that the presence of each of the three oro-buccal symptoms was significantly correlated with that of the two others. Other correlations included male gender, hallucinations, disease severity, levodopa use and lack of opiates consumption for dysarthria; disease severity, orthostatic hypotension and absence of antidepressants consumption for sialorrhea; female gender, motor fluctuations, and depressive symptoms for dysphagia. None of the three oro-buccal symptoms were associated with a reduced PDQ-39 score.
CONCLUSION: Oro-buccal symptoms were present in two of three patients with moderate PD, the presence of each symptoms being significantly correlated with that of the two others.
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS.

Entities:  

Mesh:

Year:  2011        PMID: 21453441     DOI: 10.1111/j.1468-1331.2011.03402.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  19 in total

Review 1.  Drooling in Parkinson's disease: a review.

Authors:  Prachaya Srivanitchapoom; Sanjay Pandey; Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2014-08-27       Impact factor: 4.891

2.  The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders.

Authors:  María T Gómez-Caravaca; María T Cáceres-Redondo; Ismael Huertas-Fernández; Laura Vargas-González; Fátima Carrillo; Manuel Carballo; Pablo Mir
Journal:  Neurol Sci       Date:  2014-09-20       Impact factor: 3.307

3.  The Effect of SPEAK OUT! and The LOUD Crowd on Dysarthria Due to Parkinson's Disease.

Authors:  Alison Behrman; Jennifer Cody; Samantha Elandary; Peter Flom; Shilpa Chitnis
Journal:  Am J Speech Lang Pathol       Date:  2020-05-18       Impact factor: 2.408

4.  Frenchay dysarthria assessment (FDA-2) in Parkinson's disease: cross-cultural adaptation and psychometric properties of the European Portuguese version.

Authors:  Rita Cardoso; Isabel Guimarães; Helena Santos; Rita Loureiro; Josefa Domingos; Daisy de Abreu; Nilza Gonçalves; Serge Pinto; Joaquim Ferreira
Journal:  J Neurol       Date:  2016-10-17       Impact factor: 4.849

5.  Drooling in Parkinson's Disease: Evidence of a Role for Divided Attention.

Authors:  Hannah Reynolds; Nick Miller; Richard Walker
Journal:  Dysphagia       Date:  2018-05-21       Impact factor: 3.438

6.  STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson's disease.

Authors:  Francesco Bove; Danilo Genovese; Martina Petracca; Tommaso Tufo; Danila Pisani; Maria Rita Lo Monaco; Anna Rita Bentivoglio; Paolo Calabresi; Carla Piano
Journal:  NPJ Parkinsons Dis       Date:  2022-06-29

Review 7.  Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms.

Authors:  Omid Reza Tamtaji; Russel J Reiter; Reza Alipoor; Ehsan Dadgostar; Ebrahim Kouchaki; Zatollah Asemi
Journal:  Cell Mol Neurobiol       Date:  2019-08-06       Impact factor: 5.046

8.  Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial.

Authors:  Catherine M Sackley; Christina H Smith; Caroline Rick; Marian C Brady; Natalie Ives; Ramilla Patel; Helen Roberts; Francis Dowling; Sue Jowett; Keith Wheatley; Smitaa Patel; Debbie Kelly; Gina Sands; Carl Clarke
Journal:  Trials       Date:  2014-06-07       Impact factor: 2.279

9.  Progression of voice and speech impairment in the course of Parkinson's disease: a longitudinal study.

Authors:  S Skodda; W Grönheit; N Mancinelli; U Schlegel
Journal:  Parkinsons Dis       Date:  2013-12-10

10.  Deficits in the Mimicry of Facial Expressions in Parkinson's Disease.

Authors:  Steven R Livingstone; Esztella Vezer; Lucy M McGarry; Anthony E Lang; Frank A Russo
Journal:  Front Psychol       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.